Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Terminated · Phase 1, Phase 2 · NCT05296525
Conditions: Non-Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $5,750
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 13
About the trial
- Sponsor
- Gamida Cell ltd
- Tested
- GDA-201 (drug)
- Dates
- Started 2022-07-05; completion 2024-04-22
- Results posted
- Yes
This is an open-label, non-randomized, interventional, single group assignment study of GDA-201, an allogeneic cryopreserved Natural Killer (NK) cell therapy derived from donor peripheral blood, in combination with rituximab, monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL).
From ClinicalTrials.gov, last updated 2025-03-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Gamida Cell Inc. reported $5,750 in research payments for this study in 2025 (2 payments).
Products named: Omisirge
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.